A Phase II multicenter trial to evaluate combination ipilimumab and high-dose IL-2 in patients with unresectable stage III and IV melanoma.

被引：6
|
作者：
Kaufman, Howard
Wang, Jiafeng
Curti, Brendan D.
Clark, Joseph
Ernstoff, Marc S.
Silk, Ann
Mehnert, Janice M.
Zloza, Andrew
Shih, Joe
McDermott, David F.
机构：
[1] Rush Univ, Med Ctr, Chicago, IL 60612 USA
[2] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[3] Providence Canc Ctr, Earle A Chiles Res Inst, Portland, OR USA
[4] Loyola Univ, Med Ctr, Maywood, IL 60153 USA
[5] Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03766 USA
[6] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.tps3095
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3095
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase II single-arm multicenter study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma.
    Rapisuwon, Suthee
    Patel, Sapna Pradyuman
    Carvajal, Richard D.
    Hernandez-Aya, Leonel Fernando
    Tsai, Katy K.
    Chandra, Sunandana
    Tan, Ming Tony
    Daud, Adil
    Sosman, Jeffrey Alan
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [42] Phase II trial of high-dose bolus (HOB) IL-2 in patients with metastatic melanoma (MM) who haveprogressed after biochemotherapy (BCT): Updated results.
    Agarwala, SS
    Tarhini, A
    Gooding, W
    Cai, C
    Kirkwood, JM
    Stover, LL
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 722S - 722S
  • [43] Clinical benefit of ipilimumab in patients with metastatic melanoma who progress on high-dose IL-2.
    Joseph, R. W.
    Hwu, P.
    Davies, M. A.
    Atkins, M. B.
    Sullivan, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [44] A phase II study of combined therapy with vemurafenib (vem) and high-dose interleukin-2 (aldesleukin; HD IL-2) in patients with metastatic melanoma
    Wargo, Jennifer Ann
    Lawrence, Donald P.
    Cooper, Zachary A.
    Frederick, Dennie T.
    Giobbie-Hurder, Anita
    Piris, Adriano
    Rubin, Krista M.
    Fadden, Riley
    Reuben, Alexandre
    Starker, Lee
    Flaherty, Keith
    Sharpe, Arlene
    Sullivan, Ryan J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [45] The High-Dose Aldesleukin (IL-2) "Select" Trial: A Trial Designed to Prospectively Validate Predictive Models of Response to High-Dose IL-2 Treatment in Patients With Metastatic Renal Cell Carcinoma
    Clement, Jessica M.
    McDermott, David F.
    CLINICAL GENITOURINARY CANCER, 2009, 7 (02) : E7 - E9
  • [46] Re-induction with ipilimumab, gp100 peptide vaccine, or a combination of both from a phase III, randomized, double-blind, multicenter study of previously treated patients with unresectable stage III or IV melanoma
    Hodi, F. S.
    O'Day, S.
    McDermott, D. F.
    Haanen, J. B.
    Robert, C.
    Zhu, X.
    Yellin, M. J.
    Ibrahim, R. A.
    Hoos, A.
    Wolchok, J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [47] Correlation of NRAS Mutations With Clinical Response to High-dose IL-2 in Patients With Advanced Melanoma
    Joseph, Richard W.
    Sullivan, Ryan J.
    Harrell, Robyn
    Stemke-Hale, Katherine
    Panka, David
    Manoukian, George
    Percy, Andrew
    Bassett, Roland L.
    Ng, Chaan S.
    Radvanyi, Laszlo
    Hwu, Patrick
    Atkins, Michael B.
    Davies, Michael A.
    JOURNAL OF IMMUNOTHERAPY, 2012, 35 (01) : 66 - 72
  • [48] Efficacy and genetic analysis for a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic immunotherapy, and ipilimumab combination treatment in patients with stage IIIb-IV unresectable or metastatic melanoma
    Andtbacka, Robert Hans Ingemar
    Ross, Merrick I.
    Agarwala, Sanjiv S.
    Taylor, Matthew H.
    Vetto, John T.
    Neves, Rogerio Izar
    Daud, Adil
    Khong, Hung T.
    Ungerleider, Richard S.
    Tanaka, Maki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [49] NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma
    Tarhini, Ahmad A.
    Frankel, Paul
    Ruel, Christopher
    Ernstoff, Marc S.
    Kuzel, Timothy M.
    Logan, Theodore F.
    Khushalani, Nikhil I.
    Tawbi, Hussein A.
    Margolin, Kim A.
    Awasthi, Sanjay
    Butterfield, Lisa H.
    McDermott, David
    Chen, Alice
    Lara, Primo N.
    Kirkwood, John M.
    CANCER, 2018, 124 (22) : 4332 - 4341
  • [50] Preliminary results from phase II study of combination treatment with HF10, a replication competent HSV-1 oncolytic virus, and ipilimumab in patients with stage Mb, Inc, or IV unresectable or metastatic melanoma.
    Andtbacka, Robert Hans Ingemar
    Ross, Merrick I.
    Agarwala, Sanjiv S.
    Taylor, Matthew H.
    Vetto, John T.
    Neves, Rogerio Izar
    Daud, Adil
    Khong, Hung T.
    Ungerleider, Richard S.
    Boran, Aislyn
    Tanaka, Maki
    Grossmann, Kenneth F.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345